Toxicity

• However, these treatments are polluting our rivers and could pose a health risk to pet-loving families, according to new research.
• They spread over the skin of the animal making it toxic to fleas (and sometimes ticks) for at least one month.
• They’re often sold as part of a pet healthcare plan, whereby pet owners make a monthly payment for a package of year-round treatments.
• There were multiple likely additional pathways for these chemicals to end up going down the drain.

• In my opinion, preventative flea treatment is neither necessary nor desirable in most cases.
• Non-chemical methods such as flea traps, regular hot washing of the animal’s bedding to kill larval fleas and hoovering are effective.
• There are also oral flea and tick treatments such as isoxazolines, which rapidly resolve flea infestations.

Proceed with precaution

• To make sure newer classes of parasiticide such as isoxazolines remain as effective as possible, extensive preventative use cannot continue.
• Previous research has also raised concerns about possible health risks to pet owners and veterinary professionals from chronic exposure to pet parasiticides.
• Our work supports these concerns, demonstrating that fipronil and imidacloprid readily transfer to bedding and owner’s hands, so they will quickly get smeared around the household.

Dave Goulson receives funding from the Veterinary Medicines Directorate. He is a member of the Green Party.

• "These recent data show how our oral LNC-docetaxel formulation can dramatically reduce the well-recognized toxicity of IV-docetaxel, as primarily manifested by weight loss in this model,” said James J. Ferguson, M.D., Chief Medical Officer of Matinas .
• We have now corroborated this lack of toxicity in a more comprehensive safety study with a longer treatment duration and even higher doses of oral LNC-docetaxel.
• Mice treated with oral LNC-docetaxel maintained their body weight, which was statistically no different than the weight of control mice treated with oral saline.
• The webcast will be available on the IR Calendar page of the Matinas website and will be archived for six months.

• In October 2023, Cabaletta received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) for the Phase 1/2 RESET-SSc trial.
• In November 2023, Cabaletta announced that its IND application for CABA-201 was allowed to proceed by the FDA for the Phase 1/2 RESET-MG trial.
• Cabaletta anticipates reporting initial clinical data from the Phase 1/2 RESET-MG trial in the second half of 2024.
• As of December 31, 2023, Cabaletta had cash, cash equivalents and short-term investments of $241.2 million, compared to $106.5 million as of December 31, 2022.

• The first patient was dosed in January 2024, and multiple patients are expected to be dosed in the first half of 2024.
• The Company expects to report further engraftment and protection data from the VBP101 clinical trial in the second half of 2024.
• The increase in G&A expenses was primarily attributable to an increase in personnel expenses, including an increase in share-based compensation expense.
• Net Loss: Net loss for the fourth quarter of 2023 was $26.3 million, compared to $23.9 million for the fourth quarter of 2022, and for the year ended December 31, 2023, was $117.9 million, compared to $92.1 million for the year ended December 31, 2022.